ACAD Latest Headlines

ACADIA Pharmaceuticals (ACAD) Gets a Hold from Guggenheim

at www.tipranks.com (Fri, 27-Feb 7:42 AM)

Canaccord Genuity Remains a Buy on ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Thu, 26-Feb 8:56 AM)

RBC Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Thu, 26-Feb 8:46 AM)

ACADIA Pharmaceuticals (ACAD) Receives a Buy from Needham

at www.tipranks.com (Thu, 26-Feb 7:15 AM)

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT) and ACADIA Pharmaceuticals (ACAD)

at www.tipranks.com (Thu, 26-Feb 6:30 AM)

Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA

at www.tipranks.com (Thu, 26-Feb 5:06 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Lemaitre Vascular (LMAT) and Revolution Medicines (RVMD)

at www.tipranks.com (Thu, 26-Feb 5:02 AM)

Acadia outlines 2026 revenue target up to $1.28B while advancing DAYBUE STIX and NUPLAZID growth

at seekingalpha.com (Thu, 26-Feb 1:58 AM)

ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating

at www.tipranks.com (Wed, 25-Feb 10:35 PM)

Balancing Robust Nuplazid Outlook and RADIANT Trial Uncertainty: Rationale for Maintaining a Hold on Acadia

at www.tipranks.com (Wed, 25-Feb 8:25 PM)

Acadia Pharma GAAP EPS of $1.60 beats by $1.46, revenue of $284M misses by $8.59M

at seekingalpha.com (Wed, 25-Feb 4:19 PM)

Here are the major earnings after the close Monday

at seekingalpha.com (Wed, 25-Feb 10:00 AM)